Disorder Related to Renal Transplantation Clinical Trial
— SIRESOfficial title:
Pilot Study of Selection of Either Calcineurin Inhibitor(CNI)-Based or CNI-free Immunosuppressive Regimen Depending on the Result of Pre-transplantation Donor-specific T-cell Reactivity Measured by Enzyme-linked Immunosorbent Spot(ELISPOT) in Standard-risk Kidney Recipients.
Verified date | February 2014 |
Source | Hospital Universitari de Bellvitge |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Spanish Agency of Medicines |
Study type | Interventional |
The objective is to assess if low pre-transplantation donor specific T-cell reactive patients measured by Enzyme-linked immunosorbent spot (ELISPOT)assay can be safely managed with Calcineurin inhibitor(CNI)-free Sirolimus(SRL)-based immunosuppression.
Status | Completed |
Enrollment | 61 |
Est. completion date | June 2013 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Age of donor and recipient between 18 and 65 years. 2. End-stage renal disease and scheduled to receive a primary or secondary renal allograft from a cadaveric, a living-unrelated, or a living-related donor. Patients scheduled for a second transplant must have maintained their primary graft for at least 6 months after transplantation, with the exception of graft failure due to technical reasons. 3. Panel reactive antibody (PRA) = 20%, with negative standard cross-match. 4. Women of childbearing potential must have a negative serum pregnancy test before randomization. 5. Women of childbearing potential must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months following discontinuation of assigned treatment. 6. Signed and dated informed consent prior to transplantation. Exclusion Criteria: 1. Multiple organ transplants 2. Recipients of adult or pediatric en bloc kidney transplants or dual transplantation or non-heart beating donors. 3. Evidence of active systemic or localized major infection. 4. Evidence of infiltrate, cavitation, or consolidation on chest x-ray obtained during the screening/baseline evaluation. 5. Use of any investigational drug or treatment up to 4 weeks prior to transplantation. 6. Treatment with voriconazole, ketoconazole, itraconazole, fluconazole, clotrimazole, astemizole, pimozide, terfenadine, erythromycin, clarithromycin, telithromycin, troleandomycin, rifampin, rifabutin, or St. John's Wort that is not discontinued prior to randomization. 7. Treatment with aminoglycosides, amphotericin B, cisplatin, cisapride, metoclopramide, cimetidine, bromocriptine, danazol, or other drugs associated with renal dysfunction that are not discontinued prior to randomization. 8. Subjects with a screening/baseline total white blood cell count < 2,000/mm3 or absolute neutrophil count (ANC) < 500, platelet count < 100,000/mm3. 9. Fasting triglycerides > 400 mg/dL (> 4.6 mmol/L) or fasting total cholesterol > 300 mg/dL (> 7.8 mmol/L) despite optimal lipid-lowering therapy. 10. History of malignancy within 2 years of enrollment (except for adequately treated basal cell or squamous cell carcinoma of the skin). 11. Auto-immune diseases inactive immunosuppressive treatment ( 3 months prior to inclusion). 12. Patient with psychiatric disorders that could be non-compliance for the treatment. 13. Non Caucasian patients. 14. Active peptic ulcers that could produce intestinal absorption disorders. 15. Subjects who are known to be human immunodeficiency virus(HIV) or hepatitis B virus (HBV) positive. Patients with hepatitis C virus (HCV) positive should be excluded if polymerase chain reaction (PCR) positive or transaminates values are =2 upper normal value (UNV). 16. Diabetic patients. 17. Body mass index higher than 30 Kg/m2. |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Nephrology Department. Hospital Vall d'Hebró | Barcelona | |
Spain | Nephrology Department. Hospital de Bellvitge | L'Hospitalet de Llobregat | Barcelone |
Lead Sponsor | Collaborator |
---|---|
Josep M Grinyo | Carlos III Health Institute |
Spain,
Bestard O, Crespo E, Stein M, Lúcia M, Roelen DL, de Vaal YJ, Hernandez-Fuentes MP, Chatenoud L, Wood KJ, Claas FH, Cruzado JM, Grinyó JM, Volk HD, Reinke P. Cross-validation of IFN-? Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant. 2013 Jul;13(7):1880-90. doi: 10.1111/ajt.12285. Epub 2013 Jun 13. — View Citation
Bestard O, Cruzado JM, Lucia M, Crespo E, Casis L, Sawitzki B, Vogt K, Cantarell C, Torras J, Melilli E, Mast R, Martinez-Castelao A, Gomà M, Reinke P, Volk HD, Grinyó JM. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance — View Citation
Bestard O, Cruzado JM, Mestre M, Caldés A, Bas J, Carrera M, Torras J, Rama I, Moreso F, Serón D, Grinyó JM. Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol. 2007 Oct 1;179(7):4901-9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of biopsy-confirmed acute rejection episodes | To describe cumulative biopsy-confirmed acute rejection in both groups by intention to treat analysis. | 6 months | No |
Secondary | Percentage of steroid-sensitive acute rejection episodes | To describe the percentage of steroid-sensitive acute rejections rejection in both groups by intention to treat analysis. | 6 months | No |
Secondary | Percentage of acute rejection episodes requiring treatment with antilymphocyte antibodies. | To describe the need for antibody treatment in acute rejection episodes in both groups by intention to treat analysis. | 6 months | No |
Secondary | Renal function estimated by Modification of Diet in Renal Disease (MDRD) formula. | To describe renal function measured by MDRD in both groups by intention to treat and "on therapy" analysis. | 12 months | No |
Secondary | Proteinuria measured in g/day | To describe proteinuria in g/day in both groups by intention to treat analysis. | 6 months | No |
Secondary | Histology at month 6 protocol kidney allograft biopsy | To describe histology at month 6 in both groups by intention to treat and "on therapy" analysis. | 6 months | No |
Secondary | Percentage of patients with negative ELISPOT | To describe percentage of patients with negative ELISPOT in both groups by intention to treat and "on therapy" analysis. | 6 months | No |
Secondary | Percentage of patients in group A requiring CNI introduction. | To describe the percentage of patients in group A requiring CNI introduction. | 24 months | No |
Secondary | Percentage of patients presenting adverse events requiring study withdrawal | To describe adverse events in the whole group ("screening failure" plus "intention to treat") in both treatments groups. | 24 months | Yes |
Secondary | Percentage of biopsy-confirmed acute rejection episodes | To describe cumulative biopsy-confirmed acute rejection in both groups by intention to treat analysis. | 12 months | No |
Secondary | Percentage of steroid-sensitive acute rejections rejection episodes | To describe the percentage of steroid-sensitive acute rejections rejection in both groups by intention to treat analysis. | 12 months | No |
Secondary | Percentage of acute rejection episodes requiring treatment with antilymphocyte antibodies | To describe the need for antibody treatment in acute rejection episodes in both groups by intention to treat analysis. | 12 months | No |
Secondary | Proteinuria measured in g/day | To describe proteinuria in g/day in both groups by intention to treat analysis. | 12 months | No |
Secondary | Percentage of patients with negative ELISPOT | To describe percentage of patients with negative ELISPOT in both groups by intention to treat and "on therapy" analysis. | 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02581436 -
Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR
|
N/A | |
Terminated |
NCT01561404 -
Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise
|
Phase 4 | |
Recruiting |
NCT02849899 -
Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period
|
Phase 3 | |
Not yet recruiting |
NCT01289301 -
Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant
|
Phase 4 | |
Completed |
NCT00905957 -
Transversus Abdominis Plane Block For Renal Transplant Recipients
|
N/A | |
Active, not recruiting |
NCT02843867 -
Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation
|
||
Active, not recruiting |
NCT02751099 -
Bone and Cardiovascular Disease After Kidney Transplant
|
||
Completed |
NCT01646099 -
Sun Protection of Kidney Transplant Recipients
|
N/A | |
Completed |
NCT01744067 -
The Effects of Omega-3 Fatty Acids in Renal Transplantation
|
Phase 4 | |
Active, not recruiting |
NCT03935958 -
Curcumin in Kidney Transplant Recipients
|
N/A | |
Recruiting |
NCT02513602 -
Osseointegrated Dental Implants in Kidney Transplanted Patients
|
N/A | |
Completed |
NCT01844713 -
Evaluation of Sun Protection Education for Kidney Transplant Recipients
|
N/A | |
Recruiting |
NCT01550445 -
Steroid Withdrawal Immunosuppression After Renal Transplantation
|
Phase 4 | |
Completed |
NCT02540395 -
Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation
|
N/A | |
Completed |
NCT00724022 -
Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation
|
Phase 4 | |
Terminated |
NCT00167661 -
Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT03968588 -
Standard- Versus Reduced-dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Renal Transplantation
|
Phase 4 | |
Recruiting |
NCT02515643 -
Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients
|
N/A | |
Completed |
NCT00455013 -
A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
|
Phase 2 | |
Recruiting |
NCT02843763 -
Study of Specific CD4 Tumors Th1 Responses in Renal Transplant After Occurrence of Cancer
|
N/A |